Funding for this research was provided by:
Swedish Cancer Foundation (254018006)
University of Gothenburg
Received: 30 July 2022
Accepted: 7 October 2022
First Online: 15 October 2022
: All animal treatments or procedures were approved by the local Animal Ethics Committee in Gothenburg, Sweden (permit no. Dnr 5.8.18–03598/2019) and was performed under institutional animal use and care guidelines.
: Not applicable.
: KSP and JL have filed multiple patents for the development of mammalian and bacterial vesicles for therapeutic purposes. JL owns equity in Codiak BioSciences Inc. and Exocure BioSciences Inc., and KSP is partly financed by Exocure Biosciences Inc. The other authors have no disclosures related to this study.